Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
About Us
About Us
More than 19+ years of experience in new drug R&D
19 + Years
More than 20+ years of experience in new drug R&D
Active clients worldwide
1100 +
Active clients worldwide
Clinical pharmaceutical scientists and service personnel
2000 +
Research scientists and service personnel
Laboratory floor space
73800 + Square meters of
Laboratory floor space
Successfully registered with relevant authorities
165 + Projects
Successfully registered with relevant authorities
Data as of 2023-12-31
About Medicilon

About Medicilon

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-stop R&D services for pharmaceutical enterprises and scientific research institutions around the world.

Based on the key requirements of drug R&D, we focus on meeting the demand for innovation and development. With our experience in serving domestic and foreign biomedical industries, we have built an integrated platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, to provide a comprehensive preclinical R&D service for the global biomedical industry.

About Medicilon
Learn more
MANAGEMENT TEAM
MANAGEMENT TEAM
Management Team
Chunlin Chen
Ph.D.
Founder&CEO
Learn more
Shuangqing Peng
Ph.D.
CSO
Learn more
Jinna Cai
Ph.D.
CBO
Learn more
Jian Liu
Ph.D.
President of Drug Discovery & CMC Unit
Learn more
Qingcong Lin
Ph.D.
President of Medicilon USA Corp.
Learn more
Wenjie Li
Ph.D.
VP of the CMC Unit
Learn more
Yongmei Xu
Ph.D.
R&D VP of Chemistry
Learn more
View all
CEO message
>CEO’s Message
CEO’s Message

Back in 2004, I came to Zhangjiang to establish my own research office based on my time in the US, and Medicilon was born.

From that moment on, we have forged ahead with tireless determination to help Medicilon grow in the past 19 years.

Innovation is at the core of the pharmaceutical industry, while quality is the lifeline of new drug R&D. Despite the years passing by, our principle of “innovation-driven and quality first” has remained true in the heart of every Medicilon staff. We will continue to innovate our integrated solutions by continuously improving R&D efficiency and striving to provide comprehensive preclinical R&D to all new drug developers as we build Medicilon into a leading CRO.

I sincerely hope that Medicilon can assist more and more new drug developers through increased efficiency and lower costs, help every Medicilon staff achieve brilliant results, deliver satisfactory harvests to every investor, and proudly demonstrate the benefits of Chinese medical/biomedical research capabilities to the world.

Founder & CEO:
Visiting professor, China Pharmaceutical University
chunlin-chen.png
Founder & CEO
corporate Culture
Corporate Culture
Corporate Culture

Our Vision

To provide comprehensive preclinical research for pharmaceutical companies, research institutions, and all scientific researchers around the world, and promote new drug development as a preclinical R&D outsourcing service provider.

Our Mission

To deliver high quality, innovative and cost effective services for our customers.

Our Value

Focus on Innovation

We seek to establish long-term partnerships with our clients and suppliers by promoting the development of a positive community with shared interests. We serve as a bridge between the upstream and downstream parts of the industrial chain, and seek to develop both our organization and employees through excellent operating processes and standards.

Win-Win Collaboration

We seek long-term partnerships with our clients and suppliers by establishing a community of shared interests. We serve as a bridge between the upstream and downstream parts of the industrial chain, and we yearn for development of both the organization and our employees through sound operating standards.

Clients First

We aim to satisfy our clients by fully meeting their R&D goals and by exceeding their expectations. We seek to exceed client requirements regarding quality, speed, cost, compliance and intellectual property protection working with them as a key part of their team.

Dedication

Our team is dedicated to client delivery motivated by the prospect of both career and personal growth and development. We are respectful and cooperative, as these values are essential for a harmonious, productive work environment.

We are respectful and cooperative, as these values are essential for a harmonious, productive work environment.

Learn more
Corporate History
Corporate History
20 years of efforts resulting in everyday
excellence and continuous growth
  • 2023

    Established and improved a BSL-2 laboratory for the research of cell and oncolytic virus drugs

    Expanded into new formulation R&D areas such as nanobody formulations

    Strengthened and improved the construction of a preclinical safety evaluation platform for Botanical Drug, GLP-1 New Drug Development, KRAS-targeted Drugs R&D Service, STAT3-targeted Drugs R&D Service

    Medicilon was selected into the "Science and Technology Innovation 100 Index"

    Won the 2023 "Influential Preclinical CRO Company", the Top 20 Chinese Pharmaceutical CRO Companies in 2023, the "Top 50 Chinese Pharmaceutical R&D Companies" in 2022-2023, the 2022 Chinese CXO Company Top 20 Ranking, and "Top 10 Most Influential CRO Enterprises" in the 2023 China pharmaceutical Industry Value List

  • 2022

    Establish Medicilon New Drug Open Innovation Center

    Medicilon (Hangzhou) grandly opened.

    Medicilon (Baoshan) started construction.

    The main structure of the expansion project of the drug R&D laboratory in the Medicilon Nanhui Park was fully capped.

    Medicilon has established several innovation service platforms such as antibody drug discovery platform, cell & gene therapy drug R&D service platform.

    Medicilon has successively won the "Top 20 Most Influential CXO Enterprises", "Top 100 Listed Companies on the Science and Technology Innovation Board in 2022", "Top 100 Shanghai Emerging Industry Enterprises in 2022", " 2022 Shanghai Top 100 Growth Enterprises", "Top 30 Value Listed Companies on the Science and Technology Innovation Board", "2022 China Biomedical Technology Innovation Value List 'Most Influential and Innovative CXO Enterprise'" and other honorary titles.

  • 2021

    Include in the MSCI China A-Share Index 

    AI + Laboratory Cross-Industry Collaboration 

    Establish a new chemical high-activity laboratory, PROTAC in vitro R&D platform and microRNA drug synthesis platform 

    Build a large animal drug efficacy model platform,establish a new mouse model of Middle Cerebral Artery Occlusion (MCAO)

    Innovate and develop RNA bioanalysis and detection platform, tumor immune preclinical research service platform, antibody-drug conjugate (ADC) preclinical service platform, and biotechnology drug non-human primate safety evaluation professional technical service platform

  • 2020

    Immuno-oncology integrated solutions developed for oncolytic viruses, RNAi, CAR-T and vaccine research technologies.

    PROTAC drug discovery technology platform established.

    Chemical AI technology introduced.

    Shanghai Nanhui Industrial Park opened.

    QE-HF-X mass spectrometer introduced to the Drug Metabolism and Pharmacokinetic (DMPK) Department

    DNA-encoded chemical library introduced.

    cGMP-based API production line established, based on IND, to provide CDMO services.

  • 2019

    Shanghai Medicilon Inc. listed on the Sci-Tech Innovation Board of the Shanghai Stock Exchange

    Stock Code: 688202

    Fifteenth anniversary celebrated.

    GLP and AAALAC review passed.

  • 2018

    Chemical process test platform expanded

    Bioanalysis platform established and expanded

    Cardiac safety evaluation integrated solutions improved.

  • 2017

    Preclinical cardiac safety evaluation research integrated solutions established.

    Clinical BE bioanalysis platform established.

    Inhalation and ophthalmic administration evaluation platform established.

    Registration and declaration integrated solutions established.

    Tumor center expanded.

    Experimental high-throughput Biacore equipment introduced.

    LC-MS/MS spectrometers introduced.

  • 2016

    Recognized as a “Qualified Organization for Shanghai Academicians and Expert Workstations”

    Preparation center microbial laboratory completed.

    Preparation center GMP-based pilot-scale test plant completed.

    Immuno-oncology integrated solutions established.

    Bio-tech drug bioanalysis integrated solutions established.

    Antibody Drug Conjugate (ADC) preclinical integrated solutions established.

    Generic Drug Quality Consistency Evaluation Integrated Solutions established.

    Triple Quad 6500 mass spectrometer introduced.

    New IVIS Lumina III introduced.

  • 2015

    Construction of a 10,000 m2 biological medicine (antibody) research laboratory is finished.

    Medicilon Science and Technology Association established, and first congress convened.

  • 2014

    Tenth anniversary celebrated.

    Establishment of Shanghai Academicians and Experts Workstation approved.

    Construction of a new laboratory, covering 10,000 square meters, is finished.

    Isotope biomarker service expanded.

    CFDA GLP review passed

  • 2013

    New foreign drugs for domestic pharmaceutical companies introduced.

    Three-party cooperation mode – involving a foreign company, Medicilon, and a domestic pharmaceutical company – established.

    Official government approval for Medicilon to be the holding company of MPI Preclinical Research (Shanghai) LLC granted.

  • 2012

    Complete IND filing materials provided, in accordance with CFDA and FDA standards.

    New drug R&D three-party cooperation promotion completed.

    New drug discovery project under the Twelfth Five-year Plan initiated.

    FDA/CFDA GLP project review passed.

  • 2011

    CFDA GLP certification passed

    GLP safety evaluation service provided, in accordance with CFDA and FDA standards.

    Integrated antibody R&D platform established.

  • 2010

    Fortune Capital investment received.

    CFDA GLP certification application filed.

  • 2009

    AAALAC Accreditation completed, and compliance with GLP standards for preclinical animal experiments introduced.

    Isotope experiment platform established.

    Research preparation and quality monitoring platform launched.

  • 2008

    Joint venture preclinical research service launched.

    Preclinical animal experiment facilities certified by the Shanghai Laboratory Animal Science Association.

    Non-primate experiment platform established.

  • 2007

    Joint venture company with MPI Research established.

    Construction of a new laboratory, covering 20,000 square meters, is finished.

    Non-GLP pharmaceutical and toxicological research project conducted.

    On-site CFDA review, regarding pharmacokinetics materials and their application, passed.

  • 2006

    Preclinical monkey research facilities certified by the Shanghai Forestry Bureau.

    First integrated new drug R&D service project launched.

    GLP and AAALAC training started.

    Structural biology platform established.

  • 2005

    Construction of a new laboratory, covering 2,500 square meters, completed.

    Animal experiment facilities certified by the Shanghai Municipality Science and Technology Commission.

    Reviewed by the Shanghai Laboratory Animal Science Association.

    Chemical synthesis FTE team established.

  • 2004

    Registered in Shanghai

    Chemical and biological analysis service introduced.

    First LC/MS/MS" equipment introduced.

  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
  • Company History Pictures
Prev page
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
Next page
Corporate Honor
Corporate Honor
20 years of efforts to
accomplish great Medicilon
Prev page
Next page
Learn more
GLP Laboratory for Drug Safety Evaluation, NMPA
MANAGEMENT TEAM
MANAGEMENT TEAM
NameDegree
Title
Content
Prev page Next page